Breaking News

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ

ARLINGTON, Mass., Feb. 18, 2022 (World NEWSWIRE) — Kala Prescribed drugs, Inc. (NASDAQ:KALA), nowadays declared that the Corporation granted non-statutory stock choices to a new staff as an inducement award outside the Company’s 2017 Equity Incentive Approach in accordance with NASDAQ Listing Rule 5635(c)(4).

The Enterprise granted stock options to obtain up to an aggregate of 15,000 shares of Kala Prescription drugs popular inventory to the new staff. The stock alternatives have been granted on February 15, 2022. The grant was accredited by the Payment Committee and built as an inducement product to these worker moving into into work with Kala Pharmaceuticals in accordance with NASDAQ Listing Rule 5635(c)(4). The choice award has an training value of $.77 per share, the closing price of Kala Pharmaceuticals’ typical stock on February 15, 2022. The solutions have a 10-calendar year expression and vest in excess of 4 decades, with 25% of the initial quantity of shares vesting on the to start with anniversary of the relevant employee’s new employ date and the remainder vesting in equal every month installments over the subsequent a few several years. Vesting of the alternatives is matter to the employee’s ongoing services with Kala Prescribed drugs as a result of the relevant vesting dates.

About Kala Prescription drugs, Inc.
Kala is a industrial-stage biopharmaceutical organization concentrated on the discovery, improvement, and commercialization of impressive therapies for health conditions of the eye. Kala has utilized its AMPPLIFY® mucus-penetrating particle (MPP) Drug Shipping and delivery Technology to two ocular therapies, EYSUVIS® (loteprednol etabonate ophthalmic suspension) .25% and INVELTYS® (loteprednol etabonate ophthalmic suspension) 1%. The Firm also has a pipeline of enhancement programs which includes a clinical-stage secretome solution candidate, KPI-012, originally concentrating on persistent corneal epithelial defects (PCED) and several proprietary new chemical entity (NCE) preclinical growth applications focused to tackle unmet professional medical desires, together with both of those front and again of the eye health conditions. For additional facts on Kala, make sure you stop by www.kalarx.com.

Trader Contacts:
Jill Steier
[email protected]
781-810-4086

Hannah Deresiewicz
[email protected]
212-362-1200